Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 0/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 13.49%
Price change 2019 → 2020: -4.63%
Price change 2020 → 2021: 9.48%
Price change 2021 → 2022: -0.61%
Price change 2022 → 2023: -5.69%
Price change 2023 → 2024: -5.38%
Price change 2024 → 2025: 6.92%
Price change 2025 → 2026: 6.25%
Price change 2026 (year to date): 9.32%
Financial growth
Revenue CAGR (8 years): -10.79%
Earnings CAGR (8 years): 6.78%
Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.
Debt
Debt-to-equity ratio: 0.72
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -25.83
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 4.65% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="PRM.TO" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Big Pharma Split Corp. | – | 0.72 | +17.2 % | 🔒 |
| Netcapital Inc. | – | 0.18 | +60.8 % | – |
| Big Banc Split Corp. | 6.3 | 0.59 | +1.8 % | – |
| HG Holdings, Inc. | 9.4 | 0.01 | −13.6 % | – |
| Innventure, Inc. | – | 0.16 | +2.6 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Big Pharma Split Corp. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 2.2 m | 186,006 | 8.6 % | n/a |
| 2021 | 3.8 m | 3.4 m | 90.6 % | +74.0 % |
| 2022 | 2.8 m | 2.2 m | 80.1 % | -26.7 % |
| 2023 | 218,481 | -97,886 | -44.8 % | -92.1 % |
| 2024 | 1.3 m | -377,462 | -29.1 % | +493.1 % |
| 2025 | 1.0 m | 3.1 m | 302.7 % | -21.4 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Big Pharma Split Corp.
What is the Big Pharma Split Corp. share price?
Latest recorded price: 16.02 CAD on 13/11/2026, for a market cap of 14.7 m USD.
What is the revenue of Big Pharma Split Corp.?
1.0 m USD for fiscal year 2025, with net income of 3.1 m USD (net margin 302.7 %).
Is Big Pharma Split Corp. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN CA08934P1080).
Who runs Big Pharma Split Corp.?
Louis Michael Kovacs is the company's chief executive.